X

Trial Profile

Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary)
Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms TUXEDO-1

Most Recent Events

10 May 2023 Status changed from active, no longer recruiting to completed.
13 Mar 2023 Planned primary completion date changed from 28 Jul 2022 to 28 Jul 2023.
13 Sep 2022 Results assessing quality-of-life and neurocognitive function presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com